A Phase 3 interventional study of VAY736 and Placebo in Sjögren´s Disease, sponsored by Novartis Pharmaceuticals. Recruiting at 72 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
China, India, France, Taiwan, Austria, Brazil, Colombia, Czechia, Germany, Hungary, Netherlands, Portugal, Slovakia, Spain, Switzerland, United Kingdom
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 704 studies in Fatigue with a site in United States — 91 open to participants now, 113 under way, 10 of them phase 3. Fatigue · United States.
Among the 704 studies in Fatigue with a site in United States, this one is the 28th largest by planned enrollment of the 610 interventional ones that give a count, is one of 39 that started in 2026, is one of 45 in phase 3, reaches primary completion later than 101 of the 112 other live ones, and was the 683rd registered.
2,232 studies on the registry are indexed under Fatigue; 427 are open to participants now.
Browse Fatigue studies →91 of the 704 studies in Fatigue with a site in United States are open now. Recruiting first, the newest first:
University of Iowa · Sites in United States
Ages 45–70
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
Bioligent · Sites in United States
Ages 18–60 · Healthy volunteers
Qualia Life Sciences · Sites in United States
Ages 25–75 · Healthy volunteers
University of Florida · Sites in United States
Ages 6+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 239 Fatigue studies recruiting now, 111 (46%) set no upper age limit and 98 (41%) stop at 75 or younger; 23 take children under 18; 73 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
704 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 105 · Phase 3 58 · Phase 4 26
First in 1998; this study’s year is marked. 39 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 570 is above the median of 54 across 1,760 interventional studies indexed under Fatigue.
Median enrollment 47 across the 610 interventional studies, 82 across the 86 observational. Of the 538 that completed or were terminated, 174 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 704 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Fatigue — fewer than ten, so there is no comparison to draw.
45 of the studies in Fatigue with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05474846Phase 3M.D. Anderson Cancer CenterCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | 2027-02-28 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT06085716Phase 3M.D. Anderson Cancer CenterCombination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers | 2027-08-31 |
| NCT07675135Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | 2027-10 |
| NCT07500090Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | 2027-10 |
Add all 45 to your calendar (.ics) → With an account.
Among the 704 studies in Fatigue with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
This is a double-blind, randomized, placebo-controlled multicenter 2-arm Phase III study, evaluating 300 mg ianalumab s.c. against placebo s.c. in adult participants with Sjögren's disease with high symptom burden.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VAY736 once monthly solution for injection for subcutaneous use.
Drug: VAY736
Placebo once monthly solution for injection for subcutaneous use.
Drug: Placebo
VAY736 once monthly solution for injection for subcutaneous use.
Also known as: ianalumab
Placebo once monthly solution for injection for subcutaneous use.
Change from baseline in SSSD oral dryness score
The Sjögren's Syndrome Symptom Diary (SSSD) oral dryness score is a patient-reported measure assessing severity of mouth dryness. The mouth dryness symptom is scored daily on a numerical scale (higher scores = worse symptoms).
Time frame: Baseline to Week 52
Change from baseline in SSSD summary score
The SSSD summary score is calculated over a defined time window. Each symptom is scored daily on a numerical scale (higher scores = worse symptoms).
Time frame: Baseline to Week 52
Change from baseline in ESSPRI score
The EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score is a validated patient-reported outcome assessing three symptom domains: dryness, pain and fatigue. Scores range from 0 (no symptoms) to 10 (worst imaginable symptoms).
Time frame: Baseline to Week 52
Change from baseline in stimulated whole salivary flow (sSF)
The stimulated whole salivary flow rate, is an objective functional assessment of salivary gland activity, measuring saliva production under stimulation. Higher values indicate better salivary gland function.
Time frame: Baseline to Week 52
Change from baseline in Patient's Global Assessment (PaGA) NRS score
The Patient's Global Assessment of disease activity captures the patient's overall perception of disease activity. It is assessed using a Numerical Rating Scale (NRS) from 0 to 10. Higher scores indicate worse perceived disease activity.
Time frame: Baseline to Week 52
Proportion of participants achieving SSSD response
Proportion of participants achieving a clinically meaningful improvement in the SSSD summary score at Week 52.
Time frame: Week 52
Proportion of participants achieving ESSPRI response
Proportion of participants achieving a clinically meaningful improvement in the ESSPRI score at Week 52.
Time frame: Week 52
Change from baseline in SSSD eye dryness score
The SSSD eye dryness item score is a patient-reported measure assessing severity of eye dryness. The eye dryness symptom is scored daily on a numerical scale (higher scores = worse symptoms).
Time frame: Baseline to Week 52
Change from baseline in FACIT-Fatigue score
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score is a 13-item questionnaire assessing fatigue and its impact on daily activities over the previous 7 days. Higher scores indicate less fatigue / better functioning.
Time frame: Baseline to Week 52
Change from baseline in Sjögren's-Related Quality of Life (SRQoL) score
The Sjögren's-Related Quality of Life (SRQoL) score is a disease-specific quality-of-life instrument evaluating the impact of Sjögren's disease on physical, emotional, social and daily functioning. Lower scores indicate better quality of life.
Time frame: Baseline to Week 52
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Aug 2029, 36 months after the start.
Of 27 phase 3 interventional studies under Fatigue, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
China, India, France, Taiwan, Austria, Brazil, Colombia, Czechia, Germany, Hungary, Netherlands, Portugal, Slovakia, Spain, Switzerland, United Kingdom
Austria, Brazil, Colombia, Czechia, Germany, Hungary, Netherlands, Portugal, Slovakia, Spain, Switzerland, United Kingdom
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ianalumab